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Abstract
Background: Signal transducers and activators of transcription (STATs) are involved in growth regulation of
cells. They are usually activated by phosphorylation at specific tyrosine residues. In neoplastic cells, constitutive
activation of STATs accompanies growth dysregulation and resistance to apoptosis through changes in gene
expression, such as enhanced anti-apoptotic gene expression or reduced pro-apoptotic gene expression.
Activated STAT3 is thought to play an important role in prostate cancer (PCA) progression. Because we are
interested in how persistently-activated STAT3 changes the cellular phenotype to a malignant one in prostate
cancer, we used expression vectors containing a gene for constitutively-activated STAT3, called S3c, into NRP-
152 rat and BPH-1 human benign prostatic epithelial cells.
Results: We observed that prostatic cell lines stably expressing S3c required STAT3 expression for survival,
because they became sensitive to antisense oligonucleotide for STAT3. However, S3c-transfected cells were not
sensitive to the effects of JAK inhibitors, meaning that STAT3 was constitutively-activated in these transfected cell
lines. NRP-152 prostatic epithelial cells lost the requirement for exogenous growth factors. Furthermore, we
observed that NRP-152 expressing S3c had enhanced mRNA levels of retinoic acid receptor (RAR)-α, reduced
mRNA levels of RAR-β and -γ, while BPH-1 cells transfected with S3c became insensitive to the effects of
androgen, and also to the effects of a testosterone antagonist. Both S3c-transfected cell lines grew in soft agar
after stable transfection with S3c, however neither S3c-transfected cell line was tumorigenic in severe-combined
immunodeficient mice.
Conclusions: We conclude, based on our findings, that persistently-activated STAT3 is an important molecular
marker of prostate cancer, which develops in formerly benign prostate cells and changes their phenotype to one
more closely resembling transformed prostate cells. That the S3c-transfected cell lines require the continued
expression of S3c demonstrates that a significant phenotypic change occurred in the cells. These conclusions are
based on our data with respect to loss of growth factor requirement, loss of androgen response, gain of growth
in soft agar, and changes in RAR subunit expression, all of which are consistent with a malignant phenotype in
prostate cancer. However, an additional genetic change may be required for S3c-transfected prostate cells to
become tumorigenic.
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Introduction
Signal transducers and activators of gene transcription
(STATs) are, as their name suggests, proteins that regulate
gene expression by affecting transcription. They are part of
the signal transduction pathway used by many growth fac-
tors and cytokines, and are activated by phosphorylation
of tyrosine and serine residues by up-stream kinases [1].
For example, signaling by IL-6 and other members of this
cytokine family generally induces phosphorylation of
STAT3 [1,2]. In the example given in Figure 1, IL-6-
induced binding to its receptor leads to homodimeriza-
tion of the receptor, which in turn leads to autophospho-
rylation of the cytosolic domain of gp130; this in turn
causes the phosphorylation of one of 3 kinases, JAK1,
JAK2, or Tyk 2. The activated up-stream kinase phosphor-
ylates STAT3, which allows for dimerization of STAT3
although this concept is currently being revisited, since it
has been shown in hepatic cells under inflammatory
stress, there is evidence for STAT3 association on lipid
rafts prior to phosphorylation [3,4] in association with
chaperone proteins such as Hsp90 (reviewed in [5]); how-
ever only the dimer form of STAT3 can translocate and
bind to DNA at specific binding sites, thereby directing
transcription of target genes. In benign cells, the signaling
by STAT3 is under tight regulation, so that the signal deliv-
ered to the cell is transient. However aberrant signaling by
STAT3 has been noted in many types of malignancies,
such as myeloma, head and neck cancer, breast cancer,
and prostate cancer [6-9]. Such persistent signaling by IL-
6 leading to aberrant activation of STAT3 is thought to
play a role in neoplastic progression of prostate cells [10].
Importantly, we and others have shown that malignant
prostate cells expressing persistently-activated STAT3
become dependent upon this transcription factor for sur-
vival, resulting in apoptosis [11-13]. Thus, persistently-
activated STAT3 fulfills the criteria of a proto-oncogene
[14,15].
Prostate cancer (PCA) is the second most frequently diag-
nosed non-cutaneous malignancy in American males,
affecting approximately 35% of them according to recent
data [16,17]. This translates into approximately 35,000
deaths last year in the United States alone; 189,000 new
cases were diagnosed in 2002 and over 220,000 cases were
projected for 2003 [18,19]. Moreover, in a recent report
the authors claimed that 30% of male mortality overall
may be due to prostate cancer [20]. For the most effective
therapy with the fewest side-effects, a thorough under-
standing of the genes involved in the neoplastic process is
essential. Androgens are known to play a critical role in
the tumorigenic process, with activity mediated by the
androgen receptor. Initially, prostate cancers are andro-
gen-sensitive (that is, they cease growing when deprived
of androgens or when treated with androgen receptor
antagonists, such as flutamide or bicalutamide), and
therefore most patients respond to androgen ablation
therapy. However, there are side-effects to this therapy
that make it unpleasant for the patient [21]. Even with
androgen ablation therapy, the disease often recurs and
when it does, it usually becomes androgen-insensitive or
hormone-refractory [22]. There is evidence that STAT3
activation via IL-6 plays a role in the conversion of normal
prostate cells to prostate cancer cells, and from androgen-
responsive to the androgen insensitive phenotype
[10,23,24]. The progression to androgen-independence
has been found to be associated with IL-6, with c-myc
expression, and with insulin-like growth factors, all of
which can signal through the activation of STAT3 [25-28].
STAT3 is negatively regulated by a retinoid-sensitive pro-
tein, GRIM-19, which may explain the positive effects
retinoids show against prostate cancer cells in vitro [29-
31]. Retinoid therapy for the treatment of prostate cancer
is currently being tested, due to the ability of these com-
pounds to rapidly induce apoptosis [32]. Indeed, the
recent addition of Taxotere to the pharmacopeia for pros-
tate cancer may well be due to its demonstrated effect on
retinoid receptors [33]. The regulation of the expression of
the 3 retinoid receptors type A (RAR-α, -β, and -γ) in the
progession to prostate cancer has been partially addressed
by Richter, et al., who showed the differential effects of all-
trans retinoic acid in human prostate cancer lines [34,35]
To this end we are studying the oncogenic role of STAT3
activation in rat prostate epithelial cell lines NRP-152 [36]
and human benign prostatic hyperplasia line BPH-1
[37,38]. Our main hypothesis is that constitutively-acti-
vated STAT3 (cSTAT3) plays an essential role in the devel-
opment of PCA and the maintenance of the malignant
phenotype. Because prostate epithelial cells become
hypertrophic, but rarely malignant, they are useful for
studying the progression to neoplasia to see how a rela-
tively transformation-resistant cell type becomes neoplas-
tic through cSTAT3. We previously determined that STAT3
was constitutively phosphorylated (hence activated) in
malignant NRP-154 but not in NRP-152 cells, even when
the NRP-152 cells were treated with testosterone [10]. We
hypothesized that cSTAT3 may account for the tumori-
genicity of NRP-154 cells, and therefore may play a deter-
mining role in the progression from hyperplasia to
neoplasia. To test our hypothesis, we transfected a plas-
mid containing a mutated gene for STAT3 known as S3c,
in which a Cys residue was substituted for an Ala residue,
thereby allowing the dimerization of the mutated STAT3,
which can then translocate across the nuclear membrane
and effect gene transcription in much the same way as the
phosphorphylated wild-type STAT3 gene product [14,39]
into NRP-152 and BPH-1 cells. We then examined the
phenotype of the selected transfected cells after cloning by
limit dilution. Our results, indicating that NRP-152 andMolecular Cancer 2005, 4:2 http://www.molecular-cancer.com/content/4/1/2
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BPH-1 cells underwent changes in phenotype consistent
with that of malignant cells, are presented here.
Results
Selection of Transfected NRP-152 and BPH-1 Cells
Two weeks after transfection with either pIRES or pIRES-
S3c and selection with G418, no surviving cells were
observed in the wells that received Clonfectin only.
Growth of cells was observed in all wells that received
either of the plasmids plus Clonfectin. Transfected cells
were expanded for further analysis in complete medium.
A summary of cells and clones and what their phenotypes
were is given in Table 1. To summarize briefly, since the
full results will be discussed in this section, we observed
the following changes:
NRP-152 cells require a variety of growth factors and addi-
tives in their medium (see Materials and Methods Section;
[36]); 152-pIRES cells (NRP-152 cells transfected with
pIRES-EGFP) required the same medium as NRP-152
cells. But 152-S3c cells grew in DMEM/Ham's F12 supple-
mented only with 10% newborn calf serum. Moreover,
152-S3c cells expressed EGFP (as did 152-pIRES, which
was expected since they were transfected with pIRES-
An example of cytokine-mediated activation of STAT3 Figure 1
An example of cytokine-mediated activation of STAT3. In this example, IL-6-induced binding to its receptor leads to 
homodimerization of the receptor, which in turn leads to autophosphorylation of the cytosolic domain of gp130; this in turn 
causes the phosphorylation of one of 3 kinases, JAK1, JAK2, or Tyk 2. The activated up-stream kinase phosphorylates STAT3, 
which allows for dimerization of STAT3; only the dimer can translocate and dock to DNA at target genes, thereby directing 
transcription.Molecular Cancer 2005, 4:2 http://www.molecular-cancer.com/content/4/1/2
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EGFP) and the FLAG epitope, which is part of the S3c gene
[40]. Both 152-pIRES and 152-S3c cells grew in the pres-
ence of G418.
BPH-1 cells grow in RPMI-1640 supplemented with
bovine serum; therefore this line does not have growth
factor dependence to begin with. BPH-pIRES and BPH-
S3c cells, aside from exhibiting G418 resistance, expressed
EGFP, but only BPH-S3c expressed the FLAG epitope of
the S3c gene. The evidence for these observations given in
Table 1 is presented in the rest of this section.
Expression of FLAG and EGFP in 152-S3c and BPH-S3c 
Cells Was Observed After Transfection and Selection with 
Antibiotics
After no viable cells were observed following antibiotic
treatment, we analyzed transfected cells for the presence
of the markers flanking the S3c gene on the plasmids
used, FLAG and EGFP. The analyses were done by flow
cytometry on a FACScan; also by Western blot using spe-
cific Abs, and the results are presented in Figure 2. In Pan-
els A through D, the mean fluorescence intensities of
representative clones of 152-S3c and BPH-S3c cells
stained with monoclonal Ab to FLAG plus fluorescent
goat anti-mouse F(ab2)', as well as the enhanced green flu-
orescent protein fluorescence intensities of transfected
cells, are shown. Panel A displays the anti-FLAG fluores-
cence intensity of 1 representative clone of 152-S3c (thin
line) compared to untransfected NRP-152 cells (thick
line); approximately 95% of the 152-S3c cells stained
with the anti-FLAG antibody. Similary, Panel B shows the
fluorescence intensity of anti-FLAG-stained BPH-1 cells
(thin line) compared to anti-FLAG-stained BPH-S3c clone
(thick line), where approximately 76% of the BPH-S3c
cells stained with the anti-FLAG antibody. Panels C and
D display the EGFP fluorescence for clones of 152-S3c and
BPH-S3c cells, compared with untransfected cells, respec-
tively. In Panel C, the thick line shows the fluorescence
intensity of EGFP in 152-S3c and the thin line shows the
lack of EGFP fluorescence in the untransfected NRP-152
cells. Approximately 67% of the 152-S3c cells showed
EGFP fluorescence. In Panel D, the thin line shows the
EGFP fluorescence intensity of BPH-S3c cells, while the
thick line shows it for untransfected BPH-1 cells. Approx-
imately 45% of the BPH-S3c cells showed fluorescence
due to EGFP. We concluded that in addition to antibiotic
resistance, the transfected cells expressed markers flanking
the S3c gene, and therefore we could attribute any change
in phenotype of the cells to the expression of the S3c, in
comparison to the vector-transfected cells. Panel E shows
the results of immunoprecipitation with anti-FLAG Ab,
followed by Western blot to detect EGFP. We used anti-
FLAG Ab for the immunoprecipitation because (1) a S3c-
specific Ab is not available, and (2) because all cells
express STAT3. Thus, because expression of FLAG equates
with expression of S3c specifically, immunoprecipitating
with anti-FLAG would reveal the S3c-expressing cells. As
seen in Figure 2E, the bands corresponding to 27 kD EGFP
are visible only in the lanes from 152-S3c and BPH-S3c
cells, while no EGFP bands are visible in the bands from
the parental lines NRP-152 and BPH-1 cells. Since the
EGFP gene is 3' to the S3c gene in the pIRES-S3c plasmid
we constructed (the plasmid codes for a bicistronic mes-
sage with 1 promoter for EGFP and S3c), these results con-
firm the flow cytometry data shown in Panels A through
D.
152-S3c Cells Grew in the Absence of Exogenous Growth 
Factors
To demonstrate that 152-S3c cells grew in the absence of
growth factors required by untransfected NRP-152 cells,
transfected and untransfected NRP-152 cells were grown
Table 1: Summary of transfected cells
Growth Factor G418 FLAG EGFP Growth In
Cell Plasmid Dependence Sensitivity Epitope Expression Simple Medium
NRP-152 none x x - - -
152-pIRES pIRES-EGFP x - - x -
152-S3c pIRES-S3c - - x x x
BPH-1 none n/a x - - n/a
BPH-pIRES pIRES-EGFP n/a - - x n/a
BPH-S3c pIRES-S3c n/a - x x n/a
The table summarizes the cells used or made in the experiments described. Cells were transfected with the indicated plasmid, as described in 
Materials & Methods. G418 was added at 400 µg/ml. Growth factors were those added to 152 medium, but not to 154 medium, as described in 
Materials and Methods, for NRP-152 cells and transfectants.
X = presence of characteristic; --- = absence of characteristic.Molecular Cancer 2005, 4:2 http://www.molecular-cancer.com/content/4/1/2
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FLAG and EGFP expression in representative NRP-152 and BPH-1 clones transfected with either pBABE-S3c or pIRES-S3c Figure 2
FLAG and EGFP expression in representative NRP-152 and BPH-1 clones transfected with either pBABE-S3c or pIRES-S3c. 
NRP-152 and BPH-1 cells were transfected with pBABE-S3c or pIRES-S3c, which bear the FLAG epitope on the S3c gene. 
Clones were derived by limit dilution, as described in Materials & Methods. Panels A–D: In all histograms, the marker M1 sets 
the region of positively fluorescent cells for determining the percent positive cells. Panels A & B: Fixed cells were permeabi-
lized and stained with anti-FLAG M1 Ab (Sigma), as described in Materials & Methods. Controls for staining were included, as 
described. Panel A: Transfected NRP-152 cells. Thin line = 152-S3c; thick line = NRP-152. Panel B: Transfected BPH-1 cells. 
Thin line = BPH-1; thick line = BPH-S3c. Panels C & D: NRP-152 and BPH-1 cells transfected with pIRES-S3c were analyzed 
for EGFP fluorescence, following selection. Panel C: Transfected NRP-152 cells. Thin line = NRP-152; thin line = 152-S3c. 
Panel D: Transfected BPH-1 cells. Thick line = BPH-1; thin line = BPH-S3c. Panel E: Immunoprecipitation followed by West-
ern blot showing EGFP expression in transfected NRP-152 and BPH cells. Note the lack of EGFP bands for parental lines NRP-
152 and BPH-1, whereas EGFP was detected using EGFP-specific Ab (Pharmingen) in lanes for 152-S3c and BPH-S3c. Meth-
ods: NRP-152, 152-S3c, BPH-1, and BPH-S3c cells were lysed in buffer. Equal amounts of protein in cell lysates were pre-
cleared with Protein A/G beads, then precipitated with anti-FLAG AB plus Protein A/G beads with rotation in the cold. The 
pelleted beads plus proteins were separated on 12% SDS gels, transferred to PVDF membranes, then blotted with Ab to EGFP. 
Enhanced chemifluorescence was used to reveal the 27 kD bands corresponding to EGFP.
E Molecular Cancer 2005, 4:2 http://www.molecular-cancer.com/content/4/1/2
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Growth of NRP-152, NRP-154, 152pBABE, and 152-S3c clones on 154 medium compared to growth on 152 medium Figure 3
Growth of NRP-152, NRP-154, 152pBABE, and 152-S3c clones on 154 medium compared to growth on 152 medium. 103 cells 
were seeded in microtiter wells, in the indicated medium. After incubation for 48 hr, MTT (15 µl at 25 µg/ml) were added to 
each well, and incubation was continued for 4 hr more. The formazan was dissolved in 0.1% SDS, and the absorbance was 
quantified on a DynaTech plate reader at 570 nm. Unpaired Student t-tests (InStat3 software) were performed to assess the 
statistical significance of the growth of S3c-transfected cells relative to pBABE transfected and untransfected NRP-152 cells. 
Panel A: Comparison of growth as measured by MTT absorbance at 48 hours; Panel B: Comparison of growth rates over 72 
hours.Molecular Cancer 2005, 4:2 http://www.molecular-cancer.com/content/4/1/2
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in microtiter wells. Proliferation was quantified by the
oxidation of MTT after 48 hr. Figure 3 shows the results of
these experiments. NRP-152 and 152-pIRES cells grew
more slowly in unsupplemented 154 medium than they
did in 152 medium. However, 152-S3c cells (3 represent-
ative clones, D5, A12, and H4, are shown) grew nearly as
well in 154 medium as in 152 medium, and grew signifi-
cantly better in 154 medium than either NRP-152 or 152-
pBABE cells (p < 0.001; Figure 3A). Therefore, clones of
152-S3c cells, stably transfected with pBABE-S3c, grew in
vitro as if they lost the requirement for additional growth
factors in the cell culture medium.
Stable Expression of S3c in BPH-1 Cells Resulted in STAT3-
Dependence for Survival
In order to show that the persistent expression of activated
STAT3 was required for the survival of the transfected
cells, as we have previously shown for hormone-refractory
prostate cancer cells lines [11,12], we transfected pIRES-
S3c into human BPH-1 cells [38] for studies with anti-
sense STAT3 oligonucleotides. We used BPH-1 cells and
transfected lines only for these experiments, because the
antisense oligonucleotide was designed for use in human
cells, and we wanted to maximize the efficacy of the anti-
sense oligonucleotide. Figure 4 shows that transfection of
125 nM of sense STAT3 oligonucleotide decreased viabil-
ity by only 5% at 48 hours, whereas transfection of the
same amount of antisense STAT3 oligonucleotide
decreased viability to 18% at 48 hours. Furthermore,
transfection of antisense STAT3 oligonucleotide into
untransfected BPH-1 cells did not decrease viability any
more than did transfection of sense oligonucleotide. Fig-
ure 4B shows that 24 hours after transfection with 125 nM
of antisense STAT3, BPH-S3c cells displayed a 66% reduc-
tion in intracellular STAT3 protein levels. We concluded
from these experiments that the S3c expressed in BPH-S3c
cells was functionally active, and that BPH-S3c cells were
dependent upon continued STAT3 expression for their
very survival, just like hormone-refractory prostate cancer
cell lines [11,13]. These data are more evidence for a pro-
found difference in phenotype between BPH-1 cells and
BPH-S3c cells.
152-cS3 Cells Have Decreased Expression of RAR-β and -γ 
mRNA, and Increased Expression of RAR-α mRNA
In prostate cancer cell lines and archived specimens, we
previously found that RAR-β and -γ have decreased mRNA
levels, while RAR-α mRNA increased, relative to non-
malignant prostate cell lines and the normal margins of
the same specimens [34,35]. This finding is also true of
NRP-152 and NRP-154 cells: the expression of RAR-β and
-γ is decreased in NRP-154 cells relative to NRP-152 cells.
In order to see if the same change in retinoic acid receptor
subunit expression occurred when S3c is expressed, which
is consistent with the malignant phenotype, we did the
following experiments. For these, we used 152-S3c and
152-pIRES cells, so that we could compare the RAR levels
with those of NRP-154 and parental NRP-152 cells,
because these 2 related cell lines are believed to represent
two stages in the progression and development of prostate
cancer [36,41]. Figure 5 depicts the northern blot hybrid-
ization results for RAR-β (Figure 5A) and -γ (Figure 5B) in
transfected and untransfected cells. Lane 1 in both panels
shows the hybridized mRNA for untransfected NRP-152
cells, while both lanes 2 show the hybridized band for
NRP-154 cells. Note the decreased amount of RAR-β and
-γ in lanes 2 (from NRP-154 cells, the prostatic carcinoma
line) relative to the amount in lanes 1, obtained from
NRP-152 cells, the benign prostatic hyperplasia line.
Lanes 3 show the hybridized mRNA obtained from NRP-
152 cells transfected with the vector, pIRES-EGFP, while
the bands displayed in both lanes 4 shows that when
NRP-152 cells were transfected with pIRES-S3c, the
hybridization of RAR-β and -γ decreased similarly to what
is observed in lanes 1 and 2. Figure 5C compares RAR-α
mRNA expression in the 4 cell lines: lane 1 again is NRP-
152 and lane 2 is NRP-154; there is more mRNA hybrid-
ized in lane 2 than in lane 1, and the band appears as a
doublet in lane 2 as well. Lane 3 shows the results from
NRP-152 cells transfected with pIRES-EGFP, while lane 4
shows the results from NRP-152 transfected with pIRES-
S3c: note the similar pattern to that of lanes 1 and 2 – lane
4 shows more hybridization and a doublet band for RAR-
α as well. We concluded from these results that transfec-
tion of NRP-152 cells with pIRES-S3c, but not pIRES-
EGFP, induced a change in RAR mRNA expression that is
often observed in prostate cancer cell lines and archived
specimens.
BPH-S3c Cells Were Androgen-Insensitive
In many human prostate cancers, overexpression of the
androgen receptor has been noted [42,43]. Therefore, the
development of the hormone-refractory state apparently
occurs even when there is no disruption of the expression
of the androgen receptor, at least in some prostate cells. To
clarify these contradictory data and to check for the devel-
opment of functional androgen-insensitivity, we exam-
ined the growth rate of human BPH-1 and BPH-S3c cells
in the presence and absence of dihydrotestosterone
(DHT), and also DHT in the presence of the antagonist
flutamide (F). Our results, presented in Table 2, show that
while BPH-1 cells respond to DHT and are blocked by F,
the same is not true of BPH-S3c. Thus, the persistent
expression of S3c in BPH-1 cells resulted in a functionally
androgen-insensitive state for these cells.
152-S3c Cells Lost Sensitivity to the JAK2 Inhibitor AG490
In non-malignant cells, the activation of STAT3 is effected
by a specific upstream kinase, JAK1 or JAK2 or sometimes
Tyk2. Previously we had shown that the constitutiveMolecular Cancer 2005, 4:2 http://www.molecular-cancer.com/content/4/1/2
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Functional activity of STAT3 in S3c-transfected cells Figure 4
Functional activity of STAT3 in S3c-transfected cells. Panel A: To show the functional activity of STAT3 expressed by the S3c 
gene, BPH-1 cells stably transfected with pIRES-S3c were treated with either 125 nM sense or antisense STAT3 oligonucle-
otide. Percent viability over time was determined by staining with propidium iodide, then quantifying fluorescence on a FACS-
can flow cytometer. Panel B: Treatment with 125 nM antisense STAT3 oligo reduced the amount of intracellular STAT3 
protein in the clone of BPH-S3c cells shown in 3A. Twenty-four hours after transfection, BPH-S3c cells were harvested, fixed, 
and permeabilized, then stained with antibody to STAT3, as described in Materials and Methods. Quantification was performed 
on a FACScan flow cytometer. The black line indicates the amount of intracellular STAT3 in BPH-S3c cells treated with sense 
STAT3, while the grey line shows the amount of STAT3 in BPH-S3c cells given antisense STAT3. STAT3 expression was 
reduced by 66% in this experiment.Molecular Cancer 2005, 4:2 http://www.molecular-cancer.com/content/4/1/2
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S3c expression inhibited RAR-β and -γ expression and increased expression of RAR-α in NRP-152 cells Figure 5
S3c expression inhibited RAR-β and -γ expression and increased expression of RAR-α in NRP-152 cells. Panel A: Effect of S3c 
on RAR-β mRNA levels. Panel B: Effect of S3c on RAR-γ mRNA levels. Panel C: Effect of S3c on RAR-α mRNA levels. NRP-
152, NRP-154, NRP-pBABE, and 152-S3c cells were grown to confluence, and RNA was harvested as described in Materials & 
Methods. Electrophoretic separation of RNA was followed by transfer to nitrocellulose, then hybridization with 32P-labeled 
probe, followed by autoradiography. Lane 1 = NRP-152 (rat benign prostatic hyperplasia line); lane 2 = NRP-154 (rat prostatic 
carcinoma line); lane 3 = 152-pBABE; lane 4 = 152-S3c. The comparison to 18S RNA is shown for each.
Table 2: Androgen-Insensitivity is conferred by S3C expression in BPH-1 cells
Cell nM DHT %Stimulation µM F + nM DHT %Inhibition
BPH 10 200 1 10 97
BPH-pIRES 10 250 1 10 99
BPH-S3c 10 2 1 10 -4
DU145 10 3 1 10 3
Cells were grown in 96-well plates for 72 hr, in the presence or absence of drugs (DHT = dihydrotestosterone; F = flutamide, bolded and 
underlined) as indicated. The MTT assay was used to assess proliferation. %Enhancement = (absorbance + drug/absorbance - drug) × 100; % 
Inhibition = 1-(absorbance + drug/absorbance - drug) × 100. The responses of DU145 cells, a human prostate cancer cell line that is androgen-
insensitive and resistant to flutamide, is shown for comparison.
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activation of STAT3 in NRP-154 cells rendered those cells
insensitive to apoptosis induced by the JAK2 inhibitor
AG490 [10]. In order to see if insensitivity to AG490 was
conferred on 152-S3c cells, we added AG490 to cells and
assessed apoptosis 48 hr later by annexin V binding and
PI inclusion. Table 3 shows the data we obtained.
Whereas NRP-152 and 152-pIRES cells were 45 ± 10%
and 38 ± 5% apoptotic, respectively, 48 hr after treatment
with 100 µM AG490, only 6.3 ± 3% of 152-S3c cells and
7.5 ± 4% of the NRP-154 cells were apoptotic after 100
µM AG490 treatment. We conclude from these experi-
ments that S3c expression in NRP-152 cells decreased
their sensitivity to AG490, which is consistent with what
we observed in malignant NRP-154 cells.
152-S3c Cells Grew in Soft Agar
As an in vitro indication of tumorigenic potential, soft
agar cloning assays were performed as described [44]. S3c-
transfected cells were compared to NRP-152 and to pIRES-
EGFP-transfected cells in these experiments. We observed
that 152-S3c cells grew significantly better (p < 0.0001 by
2-tailed Student t-test) in soft agar than either untrans-
fected NRP-152 or pIRES-transfected NRP-152 cells (Table
4). We conclude from these experiments that 152-S3c cells
have the potential to form tumors in vivo, whereas it has
previously been established that NRP-152 cells are not
tumorigenic [36], and we would not expect 152-pIRES
cells to be tumorigenic either.
Expression of S3c Did Not Confer Tumorigenicity on 
Benign NRP-152 Cells
Based on our previous data, especially the soft agar clon-
ing data, we expected that 152-S3c cells would form
tumors in SCID mice. However, in 3/3 experiments (in
two them, Matrigel was used to enhance tumorigenicity of
the cells), an average of 1/5 mice developed tumors; these
were 1 mm in diameter or less. We chose to use only trans-
fected NRP-152 cells for these experiments, because in cer-
tain in vivo environments, untransfected BPH-1 cells have
been observed to form tumors [38]. We conclude that
while persistent S3c expression altered the phenotype of 2
different benign prostatic hyperplasia lines in ways con-
sistent with the development of the malignant phenotype,
an additional change in gene expression may be required
for tumorigenicity in prostate cancer development.
Discussion
We have demonstrated that NRP-152 and BPH-1 cells
transfected with a constitutively-activated form of the
STAT3 gene, S3c, gained a phenotype which more closely
resembled that of NRP-154 cells. Specifically, the trans-
fected cells expressed resistance to the antibiotic G418,
and also expressed the FLAG epitope, as revealed by intra-
cellular flow cytometry following staining with anti-FLAG
Ab in Figure 2B–C, while Figure 2A shows the FLAG
expression in mock transfected cells. As additional evi-
dence of S3c expression, we looked for EGFP expression in
152-pIRES cells, since the bicistronic message from this
vector (pIRES-EGFP) places the S3c gene 3' to the EGFP, so
that S3c would have to be translated before EGFP is trans-
lated. Figure 2D shows the EGFP expression in the same
clone whose FLAG expression is shown in Figure 2C.
These results were confirmed by immunoprecipitation/
Western blot analysis, which is shown in Figure 2E,
whereupon cell lysates were precipitated with Ab to the
FLAG peptide on the S3c gene, then blotted with anti-
EGFP Ab. Only the transfected and selected 152-S3c and
BPH-S3c cells revealed EGFP bands, not the parental lines.
After obtaining these results, we characterized the pheno-
type of the transfected cells.
Parental NRP-152 cells are fastidious in their growth fac-
tor requirement, whereas NRP-154 cells and 152-S3c
clones grew in medium supplemented only with serum
(Figure 3). Therefore, we assessed the change in growth of
Table 3: NRP-152 Cells Transfected with S3c lost sensitivity to 
JAK2 inhibitor AG490
Cell S3c? Rx µM % Apoptotic +/- SD
NRP-154 YES AG490 0 8 ± 4
100 7.5 ± 5
5152-S3c YES AG490 0 7.5 ± 4
100 6.3 ± 3
152-pIRES NO AG490 0 11 ± 2
100 38 ± 5*
NRP-152 NO AG490 0 7.5 ± 4
100 45 ± 10*
Cells were placed in 60 mm wells for 48 hr with compound at the 
concentrations indicated. Zero concentration of the compound is the 
vehicle (DMSO) control. At the end of the incubation period, cells 
were harvested, washed, and stained with FITC-annexin V, to 
demonstrate apoptotic cells. Quantification of fluorescence was 
performed on a Becton-Dickinson FACScan flow cytometer using 
CellQuest software.
* p < 0.005 by Student t-test, compared to vehicle-treated cells.
Table 4: NRP-152 Cells transfected with S3c grew in soft Agar
CELL S3c? #WELLS #COLONIES +/- SEM
NRP-152 NO 12 2.6 ± 0.9
152-pIRES NO 12 5.8 ± 1.8
152-S3c YES 12 35 ± 4.5*
Cells were placed in 60 mm wells in soft agar for 10 days. Colonies of 
more than 1 mm in size were counted were counted using an 
inverted phase contrast microscope.
* p < 0.001 by Student t-testMolecular Cancer 2005, 4:2 http://www.molecular-cancer.com/content/4/1/2
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transfected NRP-152 cells by comparing their growth in
unsupplemented medium. We found that clones of 152-
S3c cells grew nearly as well as NRP-154 cells in simple
medium, whereas NRP-152 and 152-pIRES cells grew
poorly in the absence of growth factors included in the
medium (Figure 3). The change in growth factor require-
ment is one often observed for neoplastic cells, and is con-
sistent with the role of STAT3 as a proto-oncogene with
the capability of transforming benign cells into malignant
cells [15,45]. As for dependence on survival of constitu-
tively-activated STAT3, which has been observed in NIH-
3T3 transfected with S3c [40] and in hormone-refractory
prostate cancer cell lines [11], BPH-S3c cells treated with
125 nM antisense STAT3 oligonucleotides died over time,
going from 100% viable to less than 20% viable 48 hours
after transfection (Figure 4A); the reduction in viability
could be attributed to the effect of antisense STAT3 on
STAT3 protein expression, which was reduced by 66% at
24 hours after transfection (Figure 4B). These data mean
that like hormone-refractory prostate cancer cells, BPH-1
cells transfected with S3c became dependent upon the
continued expression of S3c for their survival.
As for RAR expression, we observed decreased mRNA lev-
els of RAR-β and -γ, but increased RAR-α expression in
S3c-transfected NRP-152 cells; the results shown in Figure
5 are consistent with the expression levels of these recep-
tor mRNAs previously observed by us in prostate cancer
lines [34] and in prostate cancer patient specimens [35].
These findings are echoed in those of Yang, et al., who
observed that IL-6-induced STAT3 signaling in lung epi-
thelial cell lines lead to increased RARα expression, which
was abrogated when the STAT3 DNA-binding domain was
substituted by the corresponding STAT1 domain [46]. The
importance of our results with respect to prostate cancer is
that this disease is often refractory to retinoid therapy, the
molecular basis for which is not known at this time. Our
results gives possible insight into the mechanism of retin-
oid insensitivity, and might also indicate that treatment of
prostate cancer with STAT3 inhibitors and with retinoids
may be beneficial.
In terms of androgen receptor function, S3c expression in
BPH cells changed their response to androgens so that
BPH-S3c cells were no longer stimulated by DHT, and the
growth of BPH-S3c cells was not inhibited by flutamide
treatment (Table 2). These findings with respect to the
androgen receptor and responses to DHT and flutamide
are especially important, as it may be the one of the first
indications of a direct effect of STAT3 on androgen recep-
tor responses, and may indicate a possible molecular
mechanism for the development of the hormone-refrac-
tory state in prostate cancer patients. The progression to
androgen-independence has been found to be associated
with IL-6, with c-myc expression, and with insulin-like
growth factors, all of which can signal through the activa-
tion of STAT3 [25-28]. It has been postulated that cross-
talk between STAT3 and the androgen receptor plays a
role in the development and maintenance of the hor-
mone-refractory state in prostate cancer [47]; our data
indicate that persistently-activated STAT3 may obviate the
need for expression of the androgen receptor, since the
androgen receptor did not respond to either DHT or F in
S3c-transfected BPH-1 cells (Table 2). Further work is war-
ranted in this area.
Prior to performing in vivo tumorigenicity experiments,
we wanted to see if S3c-transfected cells could grow in soft
agar as clones. We observed that S3c expression in NRP-
152 cells allowed them to grow as clones in soft agar
(Table 4). However, even though 152-S3c cells grew in
soft agar, a phenotype usually consistent with tumori-
genicity, in 3 out of 3 experiments we failed to observe
tumors in more than 20% of the mice, and these tumors
were not more than 1 mm in diameter (data not shown).
Therefore, we concluded from these data that persistent
expression of activated STAT3 alone was not sufficient to
produce tumorigenicity in prostatic epithelial cells,
although it had been sufficient in NIH-3T3 cells, as previ-
ously reported [40]. Furthermore, recent observations by
Zhang and coworkers point to an important function for
STAT3 in both tumorigenesis and metastasis formation in
leiomyosarcoma [48], due to signaling by hepatocyte
growth factor/scatter factor. Among the candidate genes
regulated by STAT3 in this regard are matrix metallopro-
teinase-2, which is essential for tumor invasion and
metastasis formation [49]. Perhaps STAT3 cooperates
with another factor regulated by hepatocyte growth fac-
tor/scatter factor, which is not expressed by either NRP-
152 or BPH-1 cells. Only more experiments will reveal
whether this is the case. Indeed, we are planning experi-
ments to see what genes are regulated by S3c, to gain
insight into the phenotypic changes induced by S3c
expression. For example, very recently it was reported that
STAT3 and the microphthalmia-associated transcription
factor were both required for optimal upregulation of c-
fos, and subsequent tumorigenicity, in NIH-3T3 cells [50].
Whether the prostatic lines NRP-152 or BPH-1 express
microphthalmia-associated transcription factor has not
been determined; the levels of c-fos in S3c-transfected lines
can be determined. As well, Dechow and coworkers
reported that transfection of S3c into mammary epithelial
cells rendered those cells tumorigenic in irradiated SCID
mice [51]; whether our results are an indication of a dif-
ference between mammary epithelial cellls and prostatic
epithelial cells or a reflection of irradiated vs. non-irradi-
ated SCID mice remains to be elucidated. As more infor-
mation is revealed about gene expression changes that
accompany the progression of prostate cancer from the
benign to the hormone-refractory state, the other geneticMolecular Cancer 2005, 4:2 http://www.molecular-cancer.com/content/4/1/2
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changes needed for tumorigenicity of S3c cells should be
revealed.
Conclusions
Our data indicate that transfection of NRP-152 and BPH-
1 prostatic epithelial cells with a gene for persistently-acti-
vated STAT3, S3c, changed the phenotype of the cells into
one resembling a malignant phenotype, thereby giving
even more importance to the role of activated STAT3 in
the transformation of normal cells into neoplastic cells.
Importantly, we found that cells expressing S3c depended
on its continued expression for survival. Two kinds of evi-
dence are presented: first, S3c-transfected cells became
sensitive to the effect of antisense STAT3 oligonucleotide.
When transfected with antisense STAT3, both BPH-S3c
and 152-S3c underwent apoptosis. Second, the S3c-trans-
fected cells were not sensitive to the commonly-used
STAT3 inhibitors, which are really JAK inhibitors, because
activation of STAT3 by the upstream JAK is not required
when S3c is expressed. We observed that growth factor-
dependent NRP-152 cells grew without growth factor sup-
plementation when transfected with S3c gene, whereas
the medium for vector-transfected NRP-152 cells still
required supplementation with growth factors. Moreover,
we observed that 152-S3c cells grew in soft agar, whereas
neither vector-transfected nor untransfected NRP-152
cells did. Furthermore, we observed that the expression of
RAR subunits in 152-S3c cells was different from vector-
transfected and untransfected NRP-152 cells, and that the
changes were consistent with what we previously
observed in specimens from prostate cancer patients, as
well as in primary prostatic epithelial cells compared with
prostate cancer cell lines [34,35]. These data may have
implications for the relative lack of sensitivity of PCA to
retinoid therapy. As for BPH-1 cells, which do not require
growth factor supplementation, we observed that when
transfected with S3c, this cell line lost its responses to tes-
tosterone and to the testosterone antagonist flutamide.
Neither of these changes was observed in vector-trans-
fected BPH-1 cells. However, neither S3c-transfected cell
line was tumorigenic when injected into SCID mice, lead-
ing us to conclude that additional genetic changes are pos-
sibly needed for tumorigenicity in prostate cells.
Methods
Cell Lines
NRP-152 and NRP-154 cells were the gift of Dr. David
Danielpour, Ireland Cancer Center, University Hospitals,
Cleveland, OH [36]. Growth factor-dependent NRP-152
cells were grown in DMEM/Ham's F12 medium (1:1;
GIBCO) supplemented with 10% newborn bovine serum
(Hyclone), 2 mM glutamine (GIBCO), epidermal growth
factor (20 ng/ml), insulin (5 µg/ml), dexamethasone (0.1
µM) and cholera toxin (10 µg/ml; all, Sigma), pH 7.3 (152
medium). NRP-154 cells were grown in DMEM/Ham's
F12 medium plus 10% newborn calf serum (154
medium). Growth factor-independent BPH-1 cells
[37,38] were the gift of Dr. Simon Hayward, Vanderbilt
University, Nashville, TN. They were grown in RPMI-1640
medium supplemented with 10% newborn bovine
serum. For transfections, cell were seeded into wells of 6-
well plates and grown until 50–80% confluent
monolayers of cells were present, as assessed by observa-
tion under inverted phase-contrast microscopy.
Transfections
Derivation of the pBABE-S3c plasmid containing a consti-
tutively-activated STAT3 gene, S3c (gift of Dr. Jacqueline
Bromberg, Memorial Sloan-Kettering Cancer Institute)
has been previously described [14,45]. The S3c gene was
excised along with its FLAG tag, and inserted into pIRES-
EGFP (Clontech), resulting in the plasmid called pIRES-
S3c. For stable transfections, Clonfectin reagent (Clon-
tech) was mixed with plasmid DNA (6 µl Clonfectin and
between 1 and 3 µg plasmid), according to the manufac-
turer's instructions. The complete medium was removed
from the plates of cells and replaced with 1.8 ml IMDM
(Invitrogen). The Clonfectin-plasmid mixtures (100 µl)
were added to the cells; replicate cultures of cells received
Clonfectin only at the time of transfections. The plasmid-
Clonfectin mixtures were left on the cells in the incubator
for 4 hr, at which time the supernatant fluids were aspi-
rated and replaced with 5 ml/well pre-warmed complete
medium. Twenty-four hr following transfections, G418
(Invitrogen) was added at a final concentration of 800 µg/
ml. The medium plus G418 was replaced 3 times/wk until
no surviving cells were observed on the Clonfectin-only
wells, usually 2 weeks. At that time, G418 was added at
100 µg/ml to maintain the transfected cells. When the
transfected cells reached confluence, they were used for
further analyses. Table 1 gives a summary of transfected
cells and phenotypes obtained.
For transient transfections, LipoFectamine 2000 in Opti-
MEM I medium (both, Invitrogen) was used according to
the manufacturer's directions. For subconfluent (~50%)
cells, 2 µl of LipoFectamine 2000 was used with varying
amounts of antisense or sense STAT3 oligonucleotide (gift
of Dr. James Karras, ISIS Pharmaceuticals). The oligonu-
cleotides were left on the cells for 6 hours before cell cul-
ture medium supplemented with 30% was added to each
well. Cells were incubated until assays were performed.
Limit-Dilution Cloning
In order to analyze clonal populations of cells, transfected
cells (pIRES-S3c or pIRES-EGFP) were harvested, diluted
to 10 cells/ml in complete medium, and seeded into
microtiter plates at 100 µl/well. The total volume of each
well was brought to 200 µl with additional medium, andMolecular Cancer 2005, 4:2 http://www.molecular-cancer.com/content/4/1/2
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the plates were incubated until growth of seeded cells was
observed, usually at 10 days to 2 weeks.
Determination of Stable Transfection by Expression of 
FLAG in 152-S3c and BPH-S3c Cells by Intracellular Flow 
Cytometry
Expression of the FLAG epitope engineered onto the con-
stitutively-activated STAT3 gene in transfected NRP-152
cells was performed by intracellular flow cytometry, as
described [52]. Briefly, 152-S3c or BPH-S3c cells were har-
vested, washed, and fixed in 4% paraformaldehyde/PBS
(Pharmingen) for 30 min on ice. Fixed cells were washed
and permeabilized with 0.1% sapononin (Pharmingen)
for 15 min at room temperature, then washed. Mouse
monoclonal Ab M1 to FLAG (Sigma) was added (1 µg/106
cells/100 µl permeabilization buffer) to the cells for 1 hr
on ice. The cells were washed 3 times, then incubated with
phycoerythrin (PE)-labeled goat anti-mouse F(ab2)'
(Caltag) for 1 hr on ice in permeabilization buffer. After
washing 3 times, cells were resuspended in 1 ml PBS and
analyzed on a Becton-Dickinson FACScan. CellQuest soft-
ware was used to acquire and analyze the fluorescence.
The Kolmogorov-Smirnov 2-sample test was used to
determine the level of significance of the change in fluo-
rescence intensity between control-stained (F(ab2)'-
stained only) and Ab-stained populations of cells, thereby
ascertaining that the populations observed in the histo-
grams were truly separate populations of cells [53].
Immunoprecipitation/Western Blot Studies
For immunoprecipitation, cells lysed in Lysis Buffer (10
mM PBS, pH 7.4, 1% NP-40, 0.5% sodium deoxycholate,
0.1% sodium dodecylsulfate (SDS), 1 mM sodium
orthovanadate, 1 mM phenylmethyl-sulfonyl fluoride, 40
µg/ml aprotinin) were precleared with Protein A/G agar-
ose (Santa Cruz Biotechnology), then precipitated with 1–
5 µg rabbit Ab (Cell Signaling or Pharmingen) plus Pro-
tein A/G (Santa Cruz Biotechnology) agarose overnight.
After washing, the beads were eluted by heating in Lae-
mmli buffer for 5 min at 95°C, followed by electro-
phoretic separation on 12% SDS-polyacrylamide gels
(Novex Nu-PAGE pre-cast gels). Transfer of separated pro-
tein species to nylon membrane (Millipore) was followed
by blocking in 10% non-fat dry milk in TBST (50 mM Tris
HCl, pH 7.4, 150 mM NaCl, 0.3% Tween 20). Incubation
of the membrane with rabbit Ab was followed by incuba-
tion with alkaline phosphatase-linked goat anti-rabbit
antibody (Amersham ECF kit). After addition of substrate
from the kit, the membranes were read by the Typhoon
imager, with ImageQuant software for resolution of
images (Molecular Dynamics).
Measurement of In Vitro Growth of Cells
NRP-152, NRP-154, BPH-1, and transfected cells were
seeded at 103cells/well in microtiter plates in appropriate
medium, as indicated. After 48 hr, 15 µl MTT (Sigma; 25
µg/ml) was added to each well for 4 hr, then the resulting
formazan was dissolved in 0.1% SDS. Absorbance was
determined at 570 nm on a Dynatech microplate reader.
Statistical determinations of significance were performed
by unpaired Student t-test for multiple independent
assays, using GraphPad software.
Determinations of Androgen Insensitivity and Presence of 
Retinoid Receptors
The effect of dihydrotestosterone (DHT) as growth ago-
nist, and the effect of flutamide (F) as growth antagonist,
was assessed by use of the MTT assay described above.
DHT and F were obtained from Boeringer-Mannheim,
and cells were treated with 1 or both drugs at concentra-
tions ranging from 1 to 100 nM for DHT, and 0.1 to 3 µM
for F. These are within the published ranges of efficacy for
these drugs [34,54]. Vehicle controls were included. Rep-
licate plates were harvested at 24, 48, 72, and 96 hrs after
treatment.
Northern blot hybridizations to detect the retinoid recep-
tors RARα, RARβ, and RARγ were performed as previously
published [34]. In brief, RNA was isolated from cells using
RNAEasy (Qiagen) and quantified spectrophotometri-
cally. RNA was separated by size on agarose gels, then
transferred to nitrocellulose membranes (Schleucher &
Schuell). The probe was labeled with 32P-dCTP (New Eng-
land Nuclear), then allowed to hybridize to the blot over-
night in hybridization buffer. After washing,
hybridization was detected by use of a PhosphoImager
(Molecular Dynamics).
Apoptosis Assays
Forty-eight hr after transient transfection, cells were har-
vested using Enzyme-Free Cell Dissociation Buffer. After
two washes with PBS, they were stained with FITC-
annexin V (5 µl/106 cells; Caltag) for 15 min at room tem-
perature. Apoptotic cells (cells staining with FITC-annexin
V) were quantified by measuring green fluorescence in
FL1 on the flow cytometer. In some experiments, cells
were also stained with propidium iodide (PI), which is
detected by the FL3 detector. CellQuest software was used
to acquire and analyze the data on a Becton-Dickinson
FACScan flow cytometer. For studies using the tyrphostin
JAK2 inhibitor AG490 (Calbiochem), the dissolved com-
pound was added to subconfluent cells, as described [11].
A vehicle control was included for the 0 µM concentra-
tion. Forty-eight hrs later, cells were harvested and proc-
essed for quantification of apoptosis by annexin V
binding and PI incorporation.
Assay for Growth in Soft Agar
Transfected cells were subjected for growth in soft agar to
assess their change in phenotype with regards to colonyMolecular Cancer 2005, 4:2 http://www.molecular-cancer.com/content/4/1/2
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formation. After selection and cloning, 104  cells were
trypsinized and washed in Ca2+/Mg2+-free PBS (Life
Technologies) and plated in 1 ml of medium plus serum
without supplements containing 0.3% (w/v) Noble Agar
(Difco/Becton-Dickinson) over a 2 ml layer of the same
medium with 0.6% agar in six-well plates. The number of
colonies was counted using low magnification micro-
scope (4×) after 10 days.
In Vivo Tumorigenicity Studies
Our protocol was reviewed and approved by the Institu-
tional Animal Care and Use Committee of UMDNJ.
Severe-combined immunodeficient (SCID) mice (Charles
River Laboratories) were obtained at 5 weeks of age, and
acclimatized in the barrier vivarium for 1 week. At that
time they were injected subcutaneously with 8 × 106 S3c
or vector-transfected (pIRES-EGFP) control cells. Each
group consisted of 5 animals. In some experiments, the
cells were mixed with Matrigel (Collaborative Research)
prior to injection. Tumor growth was monitored weekly
using engineer's caliper's to measure the 2 perpendicular
diameters, over the course of 12 weeks.
List of abbreviations
STAT signal transducer and activator of transcription
cSTAT3 constitutively-activated STAT3
JAK Janus activated kinase
PCA prostate cancer
S3c constitutively-activated STAT3 gene having a Cys
substitution
FLAG an immunogenic peptide fused to gene of protein to
be expressed for identification and/or purification
purposes
SCID severe combined immunodeficient
PBS phosphate-buffered saline
DMEM Dulbecco's modifcation of Eagle's medium




FL1, 2, or 3 fluorescence detectors on a flow cytometer
that collect fluorescence data within a
set range of wavelengths, FL1 being the lowest and FL3
being the highest
EGFP enhanced green fluorescence protein
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